Standout Papers

Certolizumab Pegol for the Treatment of Crohn's Disease 2007 2026 2013 2019 850
  1. Certolizumab Pegol for the Treatment of Crohn's Disease (2007)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine

Immediate Impact

3 from Science/Nature 125 standout
Sub-graph 1 of 19

Citing Papers

NLRC5 senses NAD+ depletion, forming a PANoptosome and driving PANoptosis and inflammation
2024 Standout
Navigating the complexities of drug development for inflammatory bowel disease
2024 Standout
16 intermediate papers

Works of S Stoĭnov being referenced

Certolizumab Pegol for the Treatment of Crohn's Disease
2007 Standout
Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease
2004
and 1 more

Author Peers

Author Last Decade Papers Cites
S Stoĭnov 755 351 234 577 8 1.2k
Juliet McColm 693 167 187 540 11 1.3k
Nathaniel Wisch 751 147 309 503 24 1.2k
Mark R. Fleisher 662 106 215 511 17 1.2k
Eric Vasiliauskas 980 129 320 801 26 1.3k
Anna Zholudev 676 142 275 460 7 1.2k
Charlotte Magdelaine–Beuzelin 813 120 175 620 11 1.2k
Michael J. Burt 405 300 410 500 27 1.3k
Deborah Woodworth 1113 197 331 775 36 1.4k
Paul Pollack 1337 166 426 1067 29 1.7k
Othmar Ludwiczek 207 260 181 320 19 1.3k

All Works

Loading papers...

Rankless by CCL
2026